Factor VIII Inhibitor
-
Emicizumab (Anti-F9 & Factor IX)
0 ImagesCat. No.: HY-P9940APureté: 99.69%Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research.
-
FXIIIa-IN-1
0 ImagesCat. No.: HY-162654CAS No.: 55909-92-7FXIIIa-IN-1 (Compound 16) is a potent and selective FXIIIa (Factor XIIIa) inhibitor with an IC50 value of 2.4 μM. FXIIIa-IN-1 inhibits FXIIIa by competing with the Gln-donor protein substrate (dimethylcasein). FXIIIa-IN-1 holds promise for the development of effective and safe novel anticoagulants.
-
TB-402
0 ImagesCat. No.: HY-P991516TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR).
-
Neutrophil elastase-IN-7
0 ImagesNeutrophil elastase-IN-7 is a human neutrophil elastase inhibitor with an IC50 of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against multiple coagulation proteins, with IC50 values of 8.2, 12.7, 1.2 and 5.7 μM against thrombin, FXa, FXIa and FXIIIa, respectively. Neutrophil elastase-IN-7 can be used in the research of cardiopulmonary diseases and inflammatory diseases.
